INLAIN UNL-CONICET phage research
Institutional account of KPC-producing Klebsiella phage/meropenem laboratory research and intended future clinical collaborations.
- Country
- Argentina
- Type
- Research
- Brief status
- Research/development
- Reviewed
Where to get Phage Therapy
A starting point for learning about phage therapy and discussing research-based options with your care team. Phage Directory is a research-focused information resource. We do not provide treatment or accept patients.
What is phage therapy?
Phage therapy uses bacteriophages—viruses that infect bacteria—to target bacterial infections. Each phage acts against particular bacteria, so a laboratory needs to find a suitable match. It is not a treatment for every infection or for illnesses without a bacterial cause. UC San Diego’s IPATH FAQ explains the basics and limitations.
Who might benefit?
Phage therapy is being studied for difficult bacterial infections, including some that resist antibiotics or persist despite treatment. It is still investigational in the United States, and a successful match or treatment outcome is not guaranteed. Your doctor needs to establish which bacteria are causing the infection and assess the available treatments. Phages may be used alongside antibiotics; they are not a reason to stop prescribed care. See Yale’s patient FAQ and IPATH’s eligibility guidance.
How to get started with your doctor
Start with your treating physician or an infectious-disease specialist. In the US, there are two main routes:
- A clinical trial: ask your doctor whether a suitable study is available and whether you meet its criteria. Trials help establish when phage therapy is safe and effective.
- Expanded access (often called compassionate use): when trial participation is not possible or feasible, a physician may explore this route for a serious or life-threatening condition with no comparable or satisfactory treatment alternative. It requires a willing provider of the investigational product, FDA authorization and appropriate institutional review. Eligibility does not guarantee access. FDA guidance for physicians.
Your physician can review prior treatment and culture results with a phage program and coordinate the next steps. IPATH advises people receiving care elsewhere to have their physician contact its team. Use a clinician-led program with appropriate laboratory testing and oversight; do not try to source or administer phages yourself.
Read these program guides first
These are useful starting points to read with your care team, not promises of treatment or current availability:
- UC San Diego — IPATH FAQ: eligibility, bacterial cultures, physician consultations and the US access process.
- Baylor College of Medicine — TAILOR: its phage research and laboratory services supporting clinicians treating challenging bacterial infections.
- Yale — Center for Phage Biology & Therapy FAQ: common questions about eligibility, treatment and continuing regular medicines.
- FDA — expanded access: the requirements and responsibilities for treatment outside a clinical trial.
For background reading:
- The Guardian’s introduction to phages (2020).
- ABC News: Dhanvi’s treatment at the Children’s Hospital at Westmead (January 2021), with the accompanying 7.30 report and transcript. The reports describe phage treatment for a serious bacterial infection in her leg.
These are historical reports, not current access guidance or a prediction of anyone else’s outcome. For medical decisions, use current program guidance with your physician.
The directory below includes international programs and studies. Access rules vary by country; a listing does not establish eligibility or availability for US patients.
Common questions about the directory
Are clinical trials and treatment programs the same?
No. Trials have specific study requirements. Treatment outside trials follows a different pathway, with rules that depend on the country. The FDA explains US expanded access.
What do “case-by-case” and “unconfirmed” mean?
Case-by-case programs assess individual requests. Unconfirmed means we couldn’t verify current availability or found conflicting information; it doesn’t mean the program has closed.
What should I confirm before making plans?
Ask about eligibility, referrals, costs and follow-up care. Countries in the list describe program or study locations; they don’t establish whether international patients can access treatment.
Resources and next steps
Resources for your care team
- United States: IPATH’s clinical FAQ and FDA expanded access.
- Europe and Georgia: France’s ANSM protocol, Poland’s Phage Therapy Unit and program listings, including two separate Georgian centers.
- India: Vitalis lists a facilitation service; it does not provide medical care.
- Australia: Phage Australia's referral information.
- Coordination and research: ASM’s Phage Therapy Coordination Network develops resources for clinical care, phage matching and manufacturing. Its proposed patient coordination platform is a future service, not a current treatment-request portal.
Phage Directory shares information and does not provide treatment. Our alert intake and clinical coordination service are paused. View past phage alerts.
The former contribution form is closed. Send general resource suggestions through Tips; it is not a treatment-request form.
Treatment programs and compassionate access
These 17 centers and networks list a current inquiry or referral route in this directory. Many assess treatment case by case. A listed route does not confirm an available treatment or appointment; your care team should check the requirements with the program.
For full records, sources and review dates, use the searchable directory below.
Australia
-
Phage Australia — Westmead; Australia. Personalized therapy for difficult infections after established approaches are optimized; adults and children; multisite treatment network.
-
Phage WA / Wal-yan Respiratory Research Centre, The Kids Research Institute Australia — Perth; Australia. Resistant infections, particularly respiratory/CF research; phage bank/matching and manufacture supporting clinical partners.
-
VICPhage Service, The Alfred — Melbourne; Australia. Assessment for adjunctive phages in challenging bacterial infections; case selection and optimized conventional management precede treatment.
-
Westmead Hospital / Westmead Institute for Medical Research phage team — Westmead; Australia. Personalized phage therapy for difficult-to-treat bacterial infections, including clinical trials and compassionate-use cases. In October 2022, STAMP administered its first patient dose of locally produced phages at Westmead.
Belgium
-
UZ Leuven Center for Bacteriophage Therapy — Leuven; Belgium. Selected severe bacterial infections after other options fail: chronic rhinosinusitis, bronchiectasis/CF respiratory infection, musculoskeletal infection and sepsis.
Canada
-
Phage Canada — National network; referral clinic in Toronto; Canada. Helps clinicians coordinate phage matching and single-patient research in Canada. Its FAQ describes fundraising for a proposed treatment center at the University of Toronto; the center is not listed as open for treatment.
-
Unity Health Toronto / St. Joseph's — Greg German — Toronto, Ontario; Canada. Selected difficult chronic bacterial infections; research leadership for P-PEAKS UTI trial and PHAGE4DAIR training.
France
-
Hospices Civils de Lyon / CRIOAc / PHAGEinLYON — Lyon; France. Multidisciplinary evaluation for exceptional compassionate use, notably difficult bone/joint and implant infections with serious functional or vital risk; matching supply and authorization required. HCL’s PETRA platform supports phage selection, testing, preparation and quality control for compassionate care and trials.
Georgia
-
Eliava Phage Therapy Center (EPTC) — Tbilisi; Georgia. Bacterial infections evaluated by internal medicine, pediatrics, urology, gynecology and outpatient surgery specialists; isolate matching and individual assessment.
-
Phage Therapy Center LTD, Tbilisi — Tbilisi; Georgia. Separate from Eliava Phage Therapy Center (EPTC). The clinic describes individualized bacterial-infection assessment and outpatient phage treatment in Tbilisi; contact the clinic to confirm current availability.
Germany
-
BG Klinikum Bergmannstrost Halle / Institute for Phage Medicine — Halle (Saale), Germany. Selected-case phage treatment for difficult bacterial infections, including bone and joint infections. The hospital announced its Institute for Phage Medicine on September 21, 2026.
-
Universitätsmedizin Frankfurt phage therapy program — Frankfurt am Main; Germany. Current inquiries limited by funding to infections involving Pseudomonas aeruginosa or Staphylococcus aureus.
-
Phage Center Regensburg / University Hospital Regensburg — Regensburg; Germany. Severe or chronic resistant/biofilm/implant-related infections after alternatives are exhausted; matching, characterization and individual compassionate treatment.
Poland
-
Hirszfeld Institute Phage Therapy Unit — Wrocław; branches in Kraków and Częstochowa; Poland. Outpatient experimental therapeutic protocol KB349/2005 for bacterial infections, including antibiotic-resistant infections.
United States
-
Pittsburgh Phage Program (P3), University of Pittsburgh/UPMC — Pittsburgh, Pennsylvania; United States. Multidisciplinary compassionate use, phage discovery/manufacturing and clinical trials; AchromoPhage adults with CF and chronic Achromobacter infection is recruiting at Pittsburgh.
-
UC San Diego IPATH — La Jolla, California; United States. Compassionate-use support for serious resistant or device-associated bacterial infections; prioritizes life/limb-threatening cases, complicated UTIs, transplant and implant-associated infections. Matching, clinical review, supply and regulatory authorization remain necessary.
-
Yale Phage Therapy Program — New Haven, Connecticut; United States. Clinical phage therapy at Yale and collaborating clinics for antibiotic-resistant bacterial infection; individualized compassionate-use eligibility.
Hospital and research programs
These institutions document clinical phage work, but current general intake is not confirmed. Some pathways are limited to selected patients or invitation-only research. The notes below distinguish those limits; contact the clinical team before making plans.
Canada
-
University of Calgary / Alberta Health Services phage research — Calgary, Alberta; Canada. Official university research-support page directs study questions to Stephen Vaughan, stephen.vaughan@albertahealthservices.ca. No general new-patient intake policy verified.
-
The Ottawa Hospital / OHRI implant infection phage research — Ottawa, Ontario; Canada. Program and registry show clinical research activity. No current general patient referral form or open phage clinic policy verified.
China
-
Anhui Medical University First Affiliated Hospital North District / Anhui Public Health Clinical Center — Anhui; China. The hospital respiratory department describes clinical phage experience for difficult lung infections. No phage-specific referral, eligibility or current patient intake was verified. General appointment booking is not confirmation of phage access.
-
Children’s Hospital of Fudan University / 复旦大学附属儿科医院 — Shanghai; China. Hospital announced launch of refractory bacterial infection clinical project on January 17, 2025 and a pediatric phage research center/joint company laboratory. No current phage referral form or open-enrollment announcement verified.
-
Jiahui International Hospital / 上海嘉会国际医院 — Shanghai; China. Official hospital/company material describes a phage-research partnership and a 2022 clinical-project announcement. Current phage intake and live ChiCTR recruitment status were not verified.
-
Shanghai Public Health Clinical Center / 上海市公共卫生临床中心 — Shanghai; China. Registry contacts Li Jie krystal_0219@163.com / +86 18017131877 and Bao Juan bj901120@dingtalk.com. Preserved V1.0 record says Not yet recruiting; planned recruitment 2025-06-01 to 2028-06-01. No phage-specific current referral form verified.
-
Zhongshan Hospital, Fudan University / 复旦大学附属中山医院 — Shanghai; China. Registry contact Li Na: li.na2@zs-hospital.sh.cn; study leader Zhu Tongyu: tyzhu@fudan.edu.cn. These are research contacts, not a verified public referral service. The registry record lists Not yet recruiting; planned recruitment 2024-03-22 to 2027-02-10.
Finland
-
HUS / University of Helsinki phage therapy collaboration — Helsinki; Finland. HUS describes treatment coordinated by infectious disease physicians, the university phage lab, hospital pharmacy and treating unit; no present standalone patient referral route established.
Germany
-
Hannover Medical School clinical phage program — Hannover; Germany. Institutional reports document individual compassionate treatments; no current public phage-specific referral route was established.
Israel
-
Israeli Phage Therapy Center — Hadassah Medical Center / Hebrew University — Jerusalem; Israel. Current Hadassah pages describe an institutional phage center/service; 2023 center paper documents clinician requests with patient information and bacterial isolates. No fresh dedicated public referral form verified. General hospital appointment/contact routes should not be relabeled as confirmed phage intake.
Singapore
-
Singapore General Hospital — Singapore; Singapore. Hospital-hosted March25,2025 article describes compassionate treatment of three patients since2024 with additional cases planned; all other care options exhausted. No current dedicated referral form or publicly recruiting study verified.
United Kingdom
-
NHS Tayside / Ninewells phage therapy program — Dundee; United Kingdom. Scottish assessment describes an experimental Tayside program; no current 2026 public patient referral or permanent service confirmed.
United States
-
University of Maryland School of Medicine — James Doub clinical research — Baltimore, Maryland; United States. Current faculty profile lists jdoub@ihv.umaryland.edu and clinical research in recalcitrant prosthetic joint infection. No current dedicated new-patient phage intake form verified.
-
Mayo Clinic Phage Therapy Program — Rochester, Minnesota; United States. Gina Suh's current institutional profile identifies her as program director and provides general appointment booking. phagetherapy@mayo.edu is published for the research biobank, whose enrollment is by invitation; it is not a verified open treatment application.
-
National Jewish Health / POSTSTAMP — Denver, Colorado; United States. POSTSTAMP (NCT06262282) is enrolling by invitation. Its protocol screens people with cystic fibrosis and persistent NTM infection for a matching phage and offers matched participants assistance seeking individual FDA compassionate-use authorization. Study participation does not guarantee phage treatment; no general open phage intake route was verified.
-
NYU Langone NTM/bronchiectasis phage program — New York, New York; United States. Institutional account describes treatment for selected patients in its NTM program. Recruiting observational biomarker study NCT07076238 lists research contacts; it does not itself provide therapeutic access.
Phage supply and support for clinicians
These organizations provide matching, preparation or product-specific expanded-access pathways. Your treating clinician remains responsible for care. Country headings locate the organizations; each policy determines where its products can be used and who may request them.
Australia
-
Monash University Phage Foundry — Melbourne; Australia. Official Monash pages describe therapeutic phage supply to VICPhage and other hospital/industry partners. Patient access is through treating clinicians/hospital services; no independent public treatment intake at the Foundry verified.
Belgium
-
Queen Astrid Military Hospital LabMCT — Brussels (Neder-over-Heembeek); Belgium. Official hospital laboratory page documents the phage bank and collaborations; no current phage-specific patient referral channel was confirmed.
Canada
-
Cytophage Technologies — Winnipeg, Manitoba; Canada. Company describes physician/hospital-partner individual-patient clinical development; no current general expanded-access application or public patient enrollment route verified.
-
Public Health Agency of Canada / NML PhageSTAR — Winnipeg, Manitoba; Canada. Federal service description identifies a clinician-facing pilot: Canadian clinicians submit purified cultures and patient information for centralized library matching and non-binding susceptibility recommendations. Exact operational submission/contact route was not located.
-
Qeen Biotechnologies — Gatineau, Québec; Canada. Qeen’s Patient Access page offers a form to ask about providing or manufacturing bacteriophages for serious bacterial infections when treatment options are exhausted. This is a supplier inquiry, not a treating clinic or a guarantee of eligibility, supply or regulatory authorization.
China
-
CreatiPhage / 创噬纪（上海）生物技术有限公司 — Shanghai; China. The company’s treatment-application page explicitly states that new treatment applications are temporarily closed; no reopening date is given. General company contact: service@cphage.com, 400-668-7738. An inquiry is not acceptance for treatment.
Denmark
-
SNIPR Biome — Copenhagen; Denmark. Official expanded-access requests to access@sniprbiome.com require a US-based patient and US-licensed, US-based physician. Company reports first patient in Phase 2 portion September 17, 2026.
Portugal
-
TechnoPhage — Lisbon; Portugal. Official TP-102 expanded-access policy accepts requests only from treating physicians, via expandedaccess@technophage.pt or the company form; case review, suitable supply and local approvals required.
Spain
-
Evolving Therapeutics — Valencia, Spain. The company publishes a general contact route on its official website and describes phage development services, including human-health applications. This is not a verified patient-intake or compassionate-use application portal. Clinical supply arrangements must be confirmed with the company and treating team.
-
I2SysBio / University of Valencia-CSIC phage group — Valencia, Spain. Produces therapeutic phages in collaboration with treating hospitals and Evolving Therapeutics. A current public supply-request or patient-intake pathway was not established.
United Kingdom
-
Great Ormond Street Hospital (GOSH) — London; United Kingdom. Official laboratory database lists phage reconstitution for resistant bacterial infections, booked through the hospital’s Cell Therapy Laboratory. This internal laboratory service is not a general external patient intake route.
United States
-
Baylor College of Medicine TAILOR — Houston, Texas; United States. Institutional service-center page offers at-cost research and personalized phage product services for clinicians; no verified dedicated patient treatment intake.
-
Intralytix — Columbia, Maryland; United States. Only a qualified licensed treating physician may request expanded access at ExpandedAccess@intralytix.com. Case-by-case review requires serious/life-threatening bacterial disease, exhausted alternatives, trial ineligibility, consent, regulatory approvals, monitoring and adequate product supply.
-
Tabula Bioscience — San Francisco, California / Madison, Wisconsin (listed work sites); United States. Policy updated July 2026 accepts physician or patient inquiries at expandedaccess@tabulabio.com. Do not send protected health information in general email; company provides secure-transmission instructions if needed. Company says physician inquiries will be acknowledged within two business days and reviewed after sufficient information within five.
-
Texas A&M Center for Phage Technology — College Station, Texas; United States. CPT supports treating physicians with phage identification and preparation, working with IPATH. Its official page directs initial suitability inquiries through the responsible physician or infectious-diseases specialist and says CPT does not diagnose or treat patients directly.
-
Tolka AI Therapeutics — Miami, Florida, United States (company office). Published limited expanded-access program accepts inquiries from physicians or patients at expandedaccess@tolka.ai; eligibility requires a treating physician to submit the formal request.
Uruguay
-
Kinzbio personalized phage supply — Montevideo; Uruguay. MSP ordinance authorizes Kinzbio's personalized phage practice; treating physicians are responsible for requesting treatment and patients must consent. Company has general inquiry emails info@kinzbio.com and admin@kinzbio.com.
Clinical trials considering participants
These 9 whole-phage studies list recruitment, invitation-only participation or expanded access. Each has its own eligibility criteria. Confirm current recruitment at each location with the study team before making plans.
Australia
-
STAMP — Recruiting. See the study record for conditions and eligibility.
No recruiting location is confirmed in this directory. Check the study source for the participating sites.
China
-
Randomized Controlled Study on the Safety and Efficacy of Phage Cocktail in the Treatment of Multidrug-Resistant Bacterial Skin Infections — Invitation only. Phage Therapy; Bacteriophage Therapy; Skin and Soft Tissue Infections
Other recorded locations (recruitment not separately confirmed): The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Russia
-
PHARAOH — Recruiting. Endocarditis, Bacterial
Sites listed as recruiting: University Clinical Hospital named after V.V.Vinogradov (branch) of the Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow, Russia.
South Korea
-
MP101-1001 — Recruiting. Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection
Sites listed as recruiting: Severance Hospital, Seoul, Seodaemun-gu, South Korea.
United States
-
ELIMINATE — Recruiting. Urinary Tract Infections
Sites listed as recruiting: Research Site 131, Lancaster, California, United States; Research Site 123, Los Angeles, California, United States; Research Site 152, Murrieta, California, United States; Research Site 137, San Diego, California, United States; Research Site 126, Tustin, California, United States; Research Site 102, Doral, Florida, United States. View all 12 recruiting sites.
-
Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients — Recruiting. Urinary Tract Infection, Recurrent
Sites listed as recruiting: University of California, San Diego, La Jolla, California, United States.
-
Phage therapy for urinary bacteria in people with spinal cord injuries — Recruiting. Bacteriuria; Spinal Cord Injuries; Asymptomatic Bacteriuria; Escherichia Coli
Sites listed as recruiting: Washington University in St Louis, St Louis, Missouri, United States; Michael E. DeBakey VA Medical Center, Houston, Texas, United States.
-
SNIPR001 for resistant E. coli in patients preparing for a stem-cell transplant — Recruiting. E Coli Infections; Allogenic Transplant Patients
Sites listed as recruiting: City of Hope, Duarte, California, United States; University of California, San Francisco, San Francisco, California, United States; John Hopkins University, Baltimore, Maryland, United States; University of Minnesota, Minneapolis, Minnesota, United States; Weill Cornell Medicine, New York, New York, United States; UPMC, Pittsburgh, Pennsylvania, United States. View all 8 recruiting sites.
-
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection — Recruiting. Cystic Fibrosis (CF); Achromobacter Infection
Sites listed as recruiting: University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Ongoing studies that are not recruiting
These studies are listed as active but are not accepting new participants.
- Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis — United States. University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States. Active, not recruiting.
- Bacteriophage Therapy in Tonsillitis — Uzbekistan. Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan. Active, not recruiting.
The full list below also includes observational and adjacent-product studies, individual-case protocols, suppliers, facilitators, planned programs, unconfirmed entries and historical records. They are not presented here as open treatment options.
Search all programs and studies
Search by condition, location or name. Use the filters for trial sites, support services or historical records. Select an entry or “Details” to open its saved record. “Website” opens the original source. Listings do not guarantee access to treatment.
About the listings and sources
We bring together current and past trials, treatment centers and companies working on phage therapy. Sources include clinical trial registries and official hospital, clinic and company websites. Some information comes from older pages or search results, and the list is incomplete.
The list starts with programs and studies. Choose All types to also include individual trial sites. A trial site is a place listed in a study; it may not offer treatment outside that trial. Study years refer to the trial, not how long a clinic has been open. Studies involving one patient, observational research and related products are labeled separately.
Use Status to include historical or closed records. Some programs consider patients case by case. “Unconfirmed” means we couldn’t verify current availability or found conflicting information. Check with the clinic or study team before making plans.
The latest entry review is the newest individual review, not a review of the whole list. Each entry shows when we last checked its sources. “Needs recheck” means it hasn’t been checked for two months; it doesn’t mean the program has closed.
Download the full list as text (Markdown) or data (JSON).
Monash Health — Clayton
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- Australia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Monash University Phage Foundry
Manufacture and matching of therapeutic phages, including Enterobacter cocktail Entelli02 for compassionate-use supply.
- Country
- Australia
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
Phage Australia
Personalized therapy for difficult infections after established approaches are optimized; adults and children; multisite treatment network.
- Country
- Australia
- Type
- Network
- Brief status
- Case-by-case; Official referral/inquiry route
- Reviewed
Phage WA / Wal-yan Respiratory Research Centre, The Kids Research Institute Australia
Resistant infections, particularly respiratory/CF research; phage bank/matching and manufacture supporting clinical partners.
- Country
- Australia
- Type
- Network
- Brief status
- Official referral/inquiry route
- Reviewed
Royal Adelaide Hospital — Adelaide
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- Australia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Royal Melbourne Hospital — Melbourne
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- Australia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Special Phage Holdings Pty Ltd
Historical phage-development company.
- Country
- Australia
- Type
- Company
- Brief status
- Acquired by AmpliPhi in 2012
- Reviewed
- Country
- Australia
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
The Alfred Hospital — Melbourne
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- Australia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
VICPhage Service, The Alfred
Assessment for adjunctive phages in challenging bacterial infections; case selection and optimized conventional management precede treatment.
- Country
- Australia
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Westmead Hospital — Westmead
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- Australia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Westmead Hospital / Westmead Institute for Medical Research phage team
Personalized phage therapy for difficult-to-treat bacterial infections, including clinical trials and compassionate-use cases. In October 2022, STAMP administered its first patient dose of locally produced phages at Westmead.
- Country
- Australia
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
diSArm (NCT05184764)
Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus
- Country
- Australia; United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
Former PhagoMed / BioNTech R&D Austria
Synthetic lysin antibacterial development; not established as a current live-phage clinic.
- Country
- Austria
- Type
- Company
- Brief status
- Historical/inactive
- Reviewed
- Country
- Bangladesh
- Type
- Trial
- Brief status
- Terminated
- Reviewed
Clinical Sciences Division, ICDDR,B, Mohakhali, — Dhaka
Recorded study locations: Diarrhea. Not an offer of treatment.
- Country
- Bangladesh
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
icddr,b
Past childhood E. coli diarrhea randomized clinical research; report states safe administration without demonstrated clinical benefit.
- Country
- Bangladesh
- Type
- Research
- Brief status
- Historical/inactive
- Reviewed
CHU Sart-Tilman — Liège
Recorded study locations: Wound Infection. Not an offer of treatment.
- Country
- Belgium
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
EPHICACI (NCT06368388)
Musculoskeletal Infection; Chronic Rhinosinusitis (Diagnosis); Persistent Bacteremia; Pulmonary Infection; Hidradenitis Suppurativa
- Country
- Belgium
- Type
- Observational study
- Brief status
- Recruiting
- Reviewed
Hopital Militaire Reine Astrid — Brussels
Recorded study locations: Wound Infection. Not an offer of treatment.
- Country
- Belgium
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Queen Astrid Military Hospital LabMCT
Phage research, characterization and clinical supply expertise associated with the military hospital.
- Country
- Belgium
- Type
- Supplier
- Brief status
- Active program; intake unconfirmed
- Reviewed
University Hospitals Leuven — Leuven
Recorded study locations: Musculoskeletal Infection; Chronic Rhinosinusitis (Diagnosis); Persistent Bacteremia; Pulmonary Infection; Hidradenitis Suppurativa. Not an offer of treatment.
- Country
- Belgium
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
UZ Leuven Center for Bacteriophage Therapy
Selected severe bacterial infections after other options fail: chronic rhinosinusitis, bronchiectasis/CF respiratory infection, musculoskeletal infection and sepsis.
- Country
- Belgium
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
PHAGOBURN (NCT02116010)
Wound Infection
- Country
- Belgium; Switzerland; France
- Type
- Trial
- Brief status
- Ended
- Reviewed
PhagoBurn consortium
P. aeruginosa/E. coli burn-wound phage development; multinational burn-unit study.
- Country
- Belgium; Switzerland; France
- Type
- Research
- Brief status
- Historical/inactive
- Reviewed
- Country
- Brazil
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
UNIFESP Escola Paulista de Medicina — KIDNAP
Feasibility/proof-of-concept oral phage trial targeting KPC-producing Klebsiella intestinal colonization in selected high-risk adults; active matching required.
- Country
- Brazil
- Type
- Center
- Brief status
- Research/development
- Reviewed
University of São Paulo CEPID B3 phage research
Institutional report of Pseudomonas phage research using in vitro and larvae models, with prospective therapeutic applications.
- Country
- Brazil
- Type
- Research
- Brief status
- Research/development
- Reviewed
Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa (NCT06798168)
Joint Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Expanded access
- Reviewed
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (NCT07228702)
Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Invitation only
- Reviewed
Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection (NCT07461337)
Prosthetic Joint Infections of Hip; Bacteriophage Therapy
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Not yet recruiting
- Reviewed
BPhage (NCT06827041)
Periprosthetic Joint Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Active, not recruiting
- Reviewed
Concordia Hospital — Winnipeg, Manitoba
Recorded study locations: Periprosthetic Joint Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Cytophage Technologies
PJI phage supply: historical 2024 case and two S. aureus candidate patients announced September 2025, subject to ethics, Health Canada and Environment Canada approvals.
- Country
- Canada
- Type
- Company
- Brief status
- Intake unconfirmed
- Reviewed
DePHEAT-PJI (NCT07698002)
Periprosthetic Infection
- Country
- Canada
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Foothills Medical Centre, University of Calgary — Calgary
Recorded study locations: Prosthetic Joint Infections of Hip; Bacteriophage Therapy. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Mixed trial statuses
- Reviewed
McGill University — Corinne Maurice phage research
Human gut microbiome and phage/IBD research expertise.
- Country
- Canada
- Type
- Research
- Brief status
- Research/development
- Reviewed
Ottawa Hospital Research Institute — Ottawa
Recorded study locations: Periprosthetic Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Ottawa Hospital Research Institute — Ottawa, Ontario
Recorded study locations: Periprosthetic Joint Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Active, not recruiting (trial)
- Reviewed
Phage Canada
Helps clinicians coordinate phage matching and single-patient research in Canada. Its FAQ describes fundraising for a proposed treatment center at the University of Toronto; the center is not listed as open for treatment.
- Country
- Canada
- Type
- Network
- Brief status
- Provider-listed inquiry route
- Reviewed
Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection (NCT06942624)
Periprosthetic Joint Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Not yet recruiting
- Reviewed
Phage Therapy for the Treatment of Urinary Tract Infection (NCT05537519)
Recurrent Urinary Tract Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Status unconfirmed
- Reviewed
PHAGE-2024-01 (NCT06456424)
Prosthetic Joint Infections of Hip; Staphylococcus Aureus Infection
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Active, not recruiting
- Reviewed
PHAGE-MOM-001 (NCT06814756)
Prosthetic Joint Infections of Hip
- Country
- Canada
- Type
- Individual-case protocol
- Brief status
- Active, not recruiting
- Reviewed
Public Health Agency of Canada / NML PhageSTAR
Phage susceptibility testing and library support for Canadian clinicians; not a treating clinic.
- Country
- Canada
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
Qeen Biotechnologies
Tailored phage development, manufacture, characterization, quality control and regulatory consultation. Institutional P-PEAKS announcement names Qeen as one of three manufacturers.
- Country
- Canada
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
South Health Campus — Calgary, Alberta
Recorded study locations: Prosthetic Joint Infections of Hip; Staphylococcus Aureus Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Active, not recruiting (trial)
- Reviewed
St. Joseph's Health Centre — Toronto, Ontario
Recorded study locations: Recurrent Urinary Tract Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Status unconfirmed (trial)
- Reviewed
The Ottawa Hospital — Ottawa
Recorded study locations: Joint Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Expanded access (trial)
- Reviewed
The Ottawa Hospital / OHRI implant infection phage research
PJI single-patient phage cases and planned dEPAnt PJI debridement/phage/antibiotic research.
- Country
- Canada
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Unity Health Toronto / St. Joseph's — Greg German
Selected difficult chronic bacterial infections; research leadership for P-PEAKS UTI trial and PHAGE4DAIR training.
- Country
- Canada
- Type
- Center
- Brief status
- Provider-listed inquiry route
- Reviewed
Université Laval Félix d'Hérelle Reference Center for Bacterial Viruses
Phage strain collection, electron microscopy identification, genomic analysis and bacterial lysogeny screening; Phage Canada names Laval as a phage bank.
- Country
- Canada
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
University of Calgary / Alberta Health Services phage research
Individual-patient PJI phage research at Calgary hospitals; registry includes MSSA, Morganella and Staphylococcus lugdunensis cases.
- Country
- Canada
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
University of Toronto bacteriophage therapy research initiative
Research support across phage biology, clinical translation and proposed Canadian center.
- Country
- Canada
- Type
- Research
- Brief status
- Research/development
- Reviewed
Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic — Vancouver, British Columbia
Recorded study locations: Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection. Not an offer of treatment.
- Country
- Canada
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
COANIQUEM phage research/regulatory development
Official August 2026 regulator meeting describes earlier clinical research with Georgia and ongoing product/regulatory development; current commercial focus mentioned includes animal dermatologic infections.
- Country
- Chile
- Type
- Research
- Brief status
- Research/development
- Reviewed
1st Medical Center of Chinese PLA General Hospital — Beijing
Recorded study locations: Pneumonia. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
8th Medical Center of Chinese PLA General Hospital — Beijing
Recorded study locations: Pneumonia. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Anhui Medical University First Affiliated Hospital North District / Anhui Public Health Clinical Center
Multidisciplinary respiratory and critical-care service describes experience with phages for multidrug-resistant lung infections.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Bacteriophage Therapy for Orthopedic Implant-Associated Infections (NCT07533292)
Orthopedic; Implant Infection
- Country
- China
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Children’s Hospital of Fudan University / 复旦大学附属儿科医院
Pediatric difficult-to-treat infections. Hospital newsletter documents nebulized personalized phages for carbapenem-resistant A. baumannii in January 2025 and describes a pediatric clinical research team.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Chinese PLA General Hospital (First and Eighth Medical Centers)
Multicenter severe multidrug-resistant Gram-negative pneumonia study combining phages with Yiqi Huoxue Jiedu traditional Chinese medicine formula.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety (NCT05973721)
Pib Specific Phage; Intractable Constipation
- Country
- China
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
CreatiPhage / 创噬纪（上海）生物技术有限公司
Phage bank, matching, formulation and partner-hospital investigator-initiated studies; pipeline describes nebulized A. baumannii pneumonia and K. pneumoniae urinary-infection applications.
- Country
- China
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
First Affiliated Hospital of Guangzhou Medical University
Site in planned severe MDR Gram-negative pneumonia trial combining phages and traditional Chinese medicine.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
First Affiliated Hospital of Guangzhou University of Chinese Medicine
Site in planned combined phage/TCM trial for severe MDR Gram-negative pneumonia.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
First Affiliated Hospital of Xi’an Jiaotong University / 西安交通大学第一附属医院
Randomized personalized phage treatment study for multidrug-resistant bacterial skin infections; separate July 2026 company announcement describes a joint phage bank.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
General Hospital of Ningxia Medical University / 宁夏医科大学总医院
MDR A. baumannii pulmonary infections; Shanghai partners matched/manufactured phages. Regional phage/bacterial-bank research continues.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Hainan Provincial People’s Hospital / 海南省人民医院
Development of MDR infection phage technology and clinical strain resources.
- Country
- China
- Type
- Research
- Brief status
- Research/development
- Reviewed
Hubei Jiangxia Laboratory / 湖北江夏实验室
MDR phage screening/engineering, clinical phage resource bank and nebulized formulations for resistant lung infection.
- Country
- China
- Type
- Research
- Brief status
- Intake unconfirmed
- Reviewed
Jiahui International Hospital / 上海嘉会国际医院
Personalized phage clinical research for difficult infections; historical program evidence only.
- Country
- China
- Type
- Center
- Brief status
- Status unconfirmed
- Reviewed
- Country
- China
- Type
- Trial lead
- Brief status
- Unverified lead
- Reviewed
Nanjing Drum Tower Hospital / 南京鼓楼医院
Pilot six-person matched-phage study for drug-resistant infections, adults 18–75, non-IV routes; English objectives emphasize urinary infection while Chinese wording is broader.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
- Country
- China
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Randomized Controlled Study on the Safety and Efficacy of Phage Cocktail in the Treatment of Multidrug-Resistant Bacterial Skin Infections (NCT07619924)
Phage Therapy; Bacteriophage Therapy; Skin and Soft Tissue Infections
- Country
- China
- Type
- Trial
- Brief status
- Invitation only
- Reviewed
Second Affiliated Hospital, Zhejiang University School of Medicine
Phage treatment research for orthopedic implant-associated infections.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Shanghai Public Health Clinical Center / 上海市公共卫生临床中心
Single-arm difficult-to-treat bacterial infection study, planned 240 participants, matched phages, non-IV routes including nebulization, topical, local injection or perfusion.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
- Country
- China
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Shanghai Tenth People's Hospital — Shanghai
Recorded study locations: Pib Specific Phage; Intractable Constipation. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Status unconfirmed (trial)
- Reviewed
Shenzhen People’s Hospital / 深圳市人民医院
ICU pneumonia caused by multidrug-resistant organisms; age 18–95 and bacteria susceptible to selected phages in the registry eligibility criteria.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
- Country
- China
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
The First Affiliated Hospital of Guangzhou Medical University — Guangdong, Guangzhou
Recorded study locations: Pneumonia. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
The First Affiliated Hospital of Guangzhou University of Chinese Medicine — Guangdong, Guangzhou
Recorded study locations: Pneumonia. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi
Recorded study locations: Phage Therapy; Bacteriophage Therapy; Skin and Soft Tissue Infections. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
the Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang
Recorded study locations: Orthopedic; Implant Infection. Not an offer of treatment.
- Country
- China
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
- Country
- China
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
- Country
- China
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Zhongshan Hospital, Fudan University / 复旦大学附属中山医院
Single-arm personalized phage study for difficult-to-treat bacterial infections; requires a matched lytic phage and a feasible non-intravenous route. Antibiotic-controlled infections and cases with IV as the only route are excluded.
- Country
- China
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Pontificia Universidad Javeriana phage research
Institutional 2021 report on Helicobacter pylori phage research; candidate isolation work rather than a clinical treatment program.
- Country
- Colombia
- Type
- Research
- Brief status
- Research/development
- Reviewed
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® (NCT06319235)
Surgical Site Infection; Staphylococcus Aureus Infection; Pseudomonas Aeruginosa Infection; Bacterial Infections; Surgical Wound Infection
- Country
- Czechia
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
MB Pharma / DUOFAG
DUOFAG topical phages for S. aureus and P. aeruginosa wounds/ulcers; official timeline reports Phase I completed July 2025, Phase IIA recruitment and Phase IIB approval February 2026.
- Country
- Czechia
- Type
- Company
- Brief status
- Research/development
- Reviewed
St. Anne's University Hospital Brno — Brno, Czech Republic
Recorded study locations: Surgical Site Infection; Staphylococcus Aureus Infection; Pseudomonas Aeruginosa Infection; Bacterial Infections; Surgical Wound Infection. Not an offer of treatment.
- Country
- Czechia
- Type
- Trial site
- Brief status
- Status unconfirmed (trial)
- Reviewed
University Hospital in Motol — Prague
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Czechia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Study With Phage for CF Subjects With Pseudomonas Lung Infection (NCT06998043)
Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF)
- Country
- Czechia; Germany; Spain; France; Ireland; Italy; Netherlands; Poland; United States
- Type
- Trial
- Brief status
- Conflicting status
- Reviewed
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection (NCT05010577)
Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis
- Country
- Czechia; Spain; Israel; Netherlands; United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants (NCT05272579)
Necrotizing Enterocolitis; Microbial Substitution
- Country
- Denmark
- Type
- Adjacent product trial
- Brief status
- Recruiting
- Reviewed
Rigshospitalet — Copenhagen
Recorded study locations: Necrotizing Enterocolitis; Microbial Substitution. Not an offer of treatment.
- Country
- Denmark
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
SNIPR Biome
Engineered CRISPR/phage programs; SNIPR001 targets E. coli, including hematologic malignancy/transplant infection-risk research.
- Country
- Denmark
- Type
- Company
- Brief status
- Provider-listed inquiry route
- Reviewed
HUS / University of Helsinki phage therapy collaboration
Experimental individualized treatment after antibiotics/usual treatment fail; lab matching and manufacture.
- Country
- Finland
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
AP-HP / PYOPHANEB multicenter study
Nebulized phages for P. aeruginosa ventilator-associated pneumonia; multicenter randomized study.
- Country
- France
- Type
- Network
- Brief status
- Intake unconfirmed
- Reviewed
Avis-PHAGEinLYON Clinic (NCT05883995)
Bone Infection
- Country
- France
- Type
- Observational study
- Brief status
- Recruiting
- Reviewed
Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc) - Hôpital de la Croix-Rousse — Lyon
Recorded study locations: Bone Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Centre hospitalier ST Joseph et St Luc — Lyon
Recorded study locations: Wound Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
CH de Tourcoing — Tourcoing
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
CH Intercommunal de Villeneuve-Saint-Georges — Villeneuve-Saint-Georges
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
CH Nantes — Nantes
Recorded study locations: Pneumonia, Ventilator-Associated. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
CHRU de Nîmes - Hôpital Universitaire de Réadaptation du Grau du Roi — Le Grau-du-Roi
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
CHRU de Toulouse - Hôpital de Rangueil — Toulouse
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
CHU Amiens — Amiens
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
CHU Angers — Angers
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
CHU Clermont-Ferrand — Clermont-Ferrand
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
CHU de Bordeaux - Hôpital Pellegrin — Bordeaux
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
CHU Nice — Nice
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
CHU Nîmes / PhagoPied multicenter study
S. aureus phages for infected diabetic foot ulcers in a randomized study; French sites.
- Country
- France
- Type
- Network
- Brief status
- Intake unconfirmed
- Reviewed
CHU Orléans — Orléans
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Department of Infectious and Tropical Diseases of the Croix Rousse Hospital of the Civil Hospitals of Lyon — Lyon
Recorded study locations: Severe Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Eligo Bioscience
Microbiome gene editing and genetic-circuit delivery using phage-derived particles, including antibacterial CRISPR approaches.
- Country
- France
- Type
- Company
- Brief status
- Research/development
- Reviewed
Hôpital Avicenne — Bobigny
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Hôpital Bicêtre — Le Kremlin-Bicêtre
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Hôpital d'instruction des armées Percy — Clamart
Recorded study locations: Wound Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Hopital européen — Marseille
Recorded study locations: Diabetic Foot; Staphylococcal Infections. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Hôpital Henri Mondor — Créteil
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Hôpital Louis Mourier — Colombes
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Hôpital Pitié-Salpêtrière — Paris
Recorded study locations: Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Hospices Civils de Lyon — Lyon
Recorded study locations: Prosthetic Joint Infection; Severe Infection; Bone and Joint Infection. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Mixed trial statuses
- Reviewed
Hospices Civils de Lyon / CRIOAc / PHAGEinLYON
Multidisciplinary evaluation for exceptional compassionate use, notably difficult bone/joint and implant infections with serious functional or vital risk; matching supply and authorization required. HCL’s PETRA platform supports phage selection, testing, preparation and quality control for compassionate care and trials.
- Country
- France
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
PHA-SA-CO (NCT04650607)
Prosthetic Joint Infection; Severe Infection
- Country
- France
- Type
- Observational study
- Brief status
- Recruiting
- Reviewed
PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL. (NCT06185920)
Severe Infection
- Country
- France
- Type
- Observational study
- Brief status
- Recruiting
- Reviewed
PHAGENIX
Site describes a specialty-pharmaceutical company established in 2025 with S. aureus, E. coli and P. aeruginosa phage portfolios.
- Country
- France
- Type
- Company
- Brief status
- Research/development
- Reviewed
PhagoDAIRI (NCT05369104)
Infection of Total Hip Joint Prosthesis; Infection of Total Knee Joint Prosthesis
- Country
- France
- Type
- Trial
- Brief status
- Ended
- Reviewed
PhagoPied (NCT02664740)
Diabetic Foot; Staphylococcal Infections
- Country
- France
- Type
- Trial
- Brief status
- Conflicting status
- Reviewed
PHASACO-retro (NCT04724603)
Bone and Joint Infection; Prosthetic Joint Infection
- Country
- France
- Type
- Observational study
- Brief status
- Status unconfirmed
- Reviewed
PHAXIAM Therapeutics / former Pherecydes pipeline
Historical S. aureus, E. coli and P. aeruginosa clinical phage development, including prosthetic joint infection and burn trials.
- Country
- France
- Type
- Company
- Brief status
- Historical/inactive
- Reviewed
Pr Tristan Ferry — Lyon
Recorded study locations: Infection of Total Hip Joint Prosthesis; Infection of Total Knee Joint Prosthesis. Not an offer of treatment.
- Country
- France
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
PYOPHANEB (NCT07804082)
Ventilator Associated Bacterial Pneumonia; Pseudomonas Aeruginosa Infection
- Country
- France
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
RECOVER (NCT06370598)
Pneumonia, Ventilator-Associated
- Country
- France
- Type
- Trial
- Brief status
- Not authorised
- Reviewed
Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate (NCT03140085)
Intravesical Bacteriophage Treatment for Urinary Tract Infections
- Country
- Georgia
- Type
- Trial
- Brief status
- Completed
- Reviewed
BioChimPharm
Human phage products targeting bacterial pathogens including staphylococci, E. coli, enterococci, Proteus, streptococci and P. aeruginosa.
- Country
- Georgia
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
Eliava BioPreparations
Company describes six marketed standard phage preparations and custom development for human, veterinary and environmental use.
- Country
- Georgia
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
Eliava Phage Therapy Center (EPTC)
Bacterial infections evaluated by internal medicine, pediatrics, urology, gynecology and outpatient surgery specialists; isolate matching and individual assessment.
- Country
- Georgia
- Type
- Center
- Brief status
- Provider-listed inquiry route
- Reviewed
George Eliava Institute of Bacteriophages, Microbiology and Virology
Phage research, collection, quality control and development; not listed as an additional patient intake clinic.
- Country
- Georgia
- Type
- Research
- Brief status
- Research/development
- Reviewed
National Center of Urology — Tbilisi
Recorded study locations: Intravesical Bacteriophage Treatment for Urinary Tract Infections. Not an offer of treatment.
- Country
- Georgia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Phage Therapy Center LTD, Tbilisi
Separate from Eliava Phage Therapy Center (EPTC). The clinic describes individualized bacterial-infection assessment and outpatient phage treatment in Tbilisi; contact the clinic to confirm current availability.
- Country
- Georgia
- Type
- Center
- Brief status
- Provider-listed inquiry route
- Reviewed
BG Klinikum Bergmannstrost Halle / Institute for Phage Medicine
Selected-case phage treatment for difficult bacterial infections, including bone and joint infections. The hospital announced its Institute for Phage Medicine on September 21, 2026.
- Country
- Germany
- Type
- Center
- Brief status
- Case-by-case; Official referral/inquiry route
- Reviewed
Bundeswehr Hospital Berlin / PhagoFlow
PhagoFlow produced P. aeruginosa phages and treated wound, urinary, ear and respiratory infections in individual attempts.
- Country
- Germany
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Charité / Phage4Cure consortium
Inhaled phage development for P. aeruginosa; PHAGE4CURE-001 healthy-volunteer study completed September 2023 to May 2025.
- Country
- Germany
- Type
- Research
- Brief status
- Research/development
- Reviewed
Department of Dermatology — Tübingen
Recorded study locations: Staphylococcus Aureus. Not an offer of treatment.
- Country
- Germany
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Department of Dermatology, University Hospital Tuebingen — Tübingen
Recorded study locations: Staphylococcus Aureus. Not an offer of treatment.
- Country
- Germany
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Hannover Medical School clinical phage program
Heart/thorax/transplant/vascular surgery experience with difficult bacterial infections; REPhRAME research partnership now includes MHH.
- Country
- Germany
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
HY-133 (NCT06290557)
Staphylococcus Aureus
- Country
- Germany
- Type
- Adjacent product trial
- Brief status
- Recruiting
- Reviewed
Phage Center Regensburg / University Hospital Regensburg
Severe or chronic resistant/biofilm/implant-related infections after alternatives are exhausted; matching, characterization and individual compassionate treatment.
- Country
- Germany
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Phage Therapeutics GmbH
Phage development for respiratory/systemic S. aureus including MRSA/MSSA and other staphylococcal infections.
- Country
- Germany
- Type
- Company
- Brief status
- Research/development
- Reviewed
- Country
- Germany
- Type
- Trial
- Brief status
- Ended
- Reviewed
Universitätsmedizin Frankfurt phage therapy program
Current inquiries limited by funding to infections involving Pseudomonas aeruginosa or Staphylococcus aureus.
- Country
- Germany
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
REPhRAME research consortium
Research project on phage therapy and microbiome restoration for recurrent urinary tract infections. The project describes a Phase Ib/IIa randomized study.
- Country
- Germany; Switzerland; Netherlands; Hungary; Slovenia; Denmark; United Kingdom; Latvia
- Type
- Network
- Brief status
- Research/development
- Reviewed
All India Institute of Medical Sciences, New Delhi
In-vitro phage therapeutic/disinfectant research against MDR A. baumannii; clinical isolates are not human phage administration.
- Country
- India
- Type
- Research
- Brief status
- Research/development
- Reviewed
Aman Hospital & Research Centre — Vadodara
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Crescent Hospital & Heart Centre — Nagpur
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
GangaGen Biotechnologies
Human phage-derived protein/lysin antibacterials including P128; company states whole-bacteriophage applications shifted to nonhuman food, veterinary, environmental and agriculture markets in 2007.
- Country
- India
- Type
- Company
- Brief status
- Research/development
- Reviewed
GSVM Medical College — Kanpur
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Institute of Medical Sciences, Banaras Hindu University / Sir Sunderlal Hospital
Customized topical phages for infected pressure ulcers in an ICU cohort; wider wound-infection clinical research leads remain separate from access.
- Country
- India
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Jupiter Hospital & Research Center — Vadodara
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
MV Hospital for Diabetes Pvt. Ltd — Chennai
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Parikh Multispeciality Healthcare Pvt. Ltd — Vadodara
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Postgraduate Institute of Medical Education and Research
E. coli/Vibrio phage research and bacterial-genome characterization.
- Country
- India
- Type
- Research
- Brief status
- Research/development
- Reviewed
Shree Siddhi Vinayak Hospital — Nashik
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Swastha Phage Solutions Pvt Ltd
Phage-based microbial therapeutic discovery and development; diagnostic/research services.
- Country
- India
- Type
- Company
- Brief status
- Research/development
- Reviewed
Vitalis Phage Therapy
Facilitation for antibiotic-resistant bacterial infections; provider/treatment decisions belong to treating physicians and partner institutions.
- Country
- India
- Type
- Facilitator
- Brief status
- Website active; facilitator
- Reviewed
Yalamanchi Hospitals & Research Centers Pvt. Ltd — Vijayawada
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- India
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
REVERSE2 (NCT05948592)
Diabetic Foot Infection
- Country
- India; Poland; United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
Mazandaran University of Medical Sciences hospital research teams
Adult COVID-19-associated secondary pneumonia and pediatric ventilator-associated pneumonia prevention studies; Razi hospital affiliation appears in adult study.
- Country
- Iran
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Nooshin Dalili — Tehran
Recorded study locations: Urinary Tract Infections; Transplant-Related Disorder. Not an offer of treatment.
- Country
- Iran
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Treatment Chronic UTI Post Kidney Transplant (NCT05967130)
Urinary Tract Infections; Transplant-Related Disorder
- Country
- Iran
- Type
- Trial
- Brief status
- Terminated
- Reviewed
Carmel Medical Center — Haifa
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Hadassah Medical Center, Ein Kerem — Jerusalem
Recorded study locations: Diabetic Foot Ulcer; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Acinetobacter Infection. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Hadassah University Medical Center — Jerusalem
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Israeli Phage Therapy Center — Hadassah Medical Center / Hebrew University
Personalized therapy for refractory/resistant infections; July 2026 Hebrew University announcement identifies current center leaders and planned P PEAKS UTI participation for recurrent E. coli infection.
- Country
- Israel
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Rambam Health Care Campus (RHCC) - Ruth Rappaport Children's Hospital — Haifa
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
REVERSE (NCT04803708)
Diabetic Foot Ulcer; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Acinetobacter Infection
- Country
- Israel
- Type
- Trial
- Brief status
- Completed
- Reviewed
Schneider Children's Medical Center of Israel — Petach Tikvah
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Tel Aviv Sourasky Medical Center — Tel Aviv
Recorded study locations: Diabetic Foot Ulcer; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Acinetobacter Infection. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The Chaim Sheba Medical Center — Ramat Gan
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Israel
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
BiomX / former Adaptive Phage Therapeutics (PhageBank)
BiomX's July 2026 SEC prospectus reports legacy phage operations substantially discontinued and a defense/security strategy pivot. BX004 phase 2b was discontinued December 8, 2025; former Israeli operating company entered insolvency, and APT facility lease ended December 31, 2025.
- Country
- Israel; United States
- Type
- Company
- Brief status
- Historical/inactive
- Reviewed
Jichi Medical University, Bacteriology
AMR-oriented phage drug discovery, bacterial surveillance and engineered phage/capsid approaches.
- Country
- Japan
- Type
- Research
- Brief status
- Research/development
- Reviewed
Osaka Metropolitan University Hospital — acne phage trial
Topical whole-bacteriophage gel for acne vulgaris twice daily for84days; target15, ages>=12. Native registry displays registration12/01/2024 and first enrollment03/07/2024 without resolving date-format ambiguity.
- Country
- Japan
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
- Country
- Japan
- Type
- Trial
- Brief status
- Not recruiting
- Reviewed
University of Osaka, RIMD Fujimoto Laboratory
Microbiome/pathobiont targeting, phage-derived lytic enzymes, clinical translation. jRCTs051230164 is hosted clinically at Osaka Metropolitan University Hospital.
- Country
- Japan
- Type
- Research
- Brief status
- Research/development
- Reviewed
Waseda University Phage Therapy Institute
Phage cocktail research and technical/ethical preparation for clinical implementation.
- Country
- Japan
- Type
- Research
- Brief status
- Research/development
- Reviewed
Kenya Institute of Primate Research
Preclinical/public-health phage research for AMR.
- Country
- Kenya
- Type
- Research
- Brief status
- Research/development
- Reviewed
Kenya Medical Research Institute
Phage research intended to complement AMR control and future therapeutics.
- Country
- Kenya
- Type
- Research
- Brief status
- Research/development
- Reviewed
- Country
- Location not listed
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis (NCT05240300)
Atopic Dermatitis
- Country
- Location not listed
- Type
- Trial
- Brief status
- Withdrawn
- Reviewed
ACTIVE1 (NCT05269121)
Prosthetic Joint Infection; Bacterial Infections
- Country
- Location not listed
- Type
- Trial
- Brief status
- Withdrawn
- Reviewed
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia (NCT07202234)
VAP - Ventilator Associated Pneumonia
- Country
- Location not listed
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection (NCT07429162)
Mycobacterium Abscessus Infection; Bacteriophage Therapy; Pulmonary Disease
- Country
- Location not listed
- Type
- Individual-case protocol
- Brief status
- Not yet recruiting
- Reviewed
BT100 (NCT05498363)
Bacterial Infections
- Country
- Location not listed
- Type
- Observational study
- Brief status
- Completed
- Reviewed
Effect of PreforPro® on Urinary and Vaginal Health (NCT05590195)
Bacterial Vaginosis; Bacterial Infections; Bacterial Vaginosis | Vaginal | Microbiology; Vaginal Infection
- Country
- Location not listed
- Type
- Adjacent product trial
- Brief status
- Status unconfirmed
- Reviewed
- Country
- Location not listed
- Type
- Expanded access
- Brief status
- Unavailable
- Reviewed
- Country
- Location not listed
- Type
- Expanded access
- Brief status
- Unavailable
- Reviewed
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia (NCT04636554)
Covid19; Bacteremia; Septicemia; Acinetobacter Baumannii Infection; Pseudomonas Aeruginosa Infection; Staph Aureus Infection
- Country
- Location not listed
- Type
- Expanded access
- Brief status
- Unavailable
- Reviewed
PHAGE Study: Bacteriophages as Novel Prebiotics (NCT03269617)
Gastrointestinal Disorder, Functional
- Country
- Location not listed
- Type
- Adjacent product trial
- Brief status
- Completed
- Reviewed
Phage Therapy (NCT07382271)
Urinary Tract Infections; Urinary Tract Infections Caused by Drug-resistant Bacteria
- Country
- Location not listed
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
- Country
- Location not listed
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients (NCT04323475)
Wound Infection
- Country
- Location not listed
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections (NCT07280598)
CF - Cystic Fibrosis; Klebsiella Pneumoniae Infection; E Coli Infections; Staphylococcus Aureus Infection; Achromobacter; Stenotrophomonas Maltophilia Infection
- Country
- Location not listed
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Amsterdam Medical Center — Amsterdam
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Netherlands
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
UMC Utrecht personalized phage therapy program
Personalized phage therapy research and reported clinical use; a planned study concerns recurrent urinary tract infections.
- Country
- Netherlands
- Type
- Center
- Brief status
- Case-by-case; Intake unconfirmed
- Reviewed
University Medical Center Utrecht — Utrecht
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Netherlands
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
- Country
- Netherlands; Portugal
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
University of Otago phage research
Genomics-led phage development and microbial-defense research; clinical translation research rather than documented current patient service.
- Country
- New Zealand
- Type
- Research
- Brief status
- Research/development
- Reviewed
Experimental Phage Therapy of Bacterial Infections (NCT00945087)
Bacterial Infections
- Country
- Poland
- Type
- Trial
- Brief status
- Status unconfirmed
- Reviewed
Hirszfeld Institute Phage Therapy Unit
Outpatient experimental therapeutic protocol KB349/2005 for bacterial infections, including antibiotic-resistant infections.
- Country
- Poland
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences — Wroclaw
Recorded study locations: Bacterial Infections. Not an offer of treatment.
- Country
- Poland
- Type
- Trial site
- Brief status
- Status unconfirmed (trial)
- Reviewed
TechnoPhage
TP-102 investigational topical phages for infected diabetic foot/nonhealing wounds involving S. aureus, P. aeruginosa or A. baumannii; separate TP-122 respiratory development.
- Country
- Portugal
- Type
- Company
- Brief status
- Provider-listed inquiry route
- Reviewed
Budgetary Healthcare Institution of Arkhangelsk Region "Severodvinsk City Clinical Emergency Hospital # 2" — Severodvinsk, Arkhangelskaya oblast
Recorded study locations: Trauma Injury; Brain Injuries; Abdominal Sepsis; Pancreatitis; Meningitis; Encephalitis; Seizures; Acute Respiratory Distress Syndrome. Not an offer of treatment.
- Country
- Russia
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
NPO Microgen
Commercial bacteriophage preparations including Sextaphag, Intestiphag, Piophag, Staphilophag and Klebsiphag.
- Country
- Russia
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
PHARAOH (NCT06870409)
Endocarditis, Bacterial
- Country
- Russia
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Research and Production Center Micromir
Company describes a phage bank and registered pharmaceutical substances usable in magistral formulations; separately markets hygiene/cosmetic phage gels.
- Country
- Russia
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
RUDN / V.V. Vinogradov Clinical Hospital PHARAOH
Randomized phage-plus-antibiotic treatment study for infective endocarditis; planned enrollment 30.
- Country
- Russia
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
SGDC-VAP (NCT04325685)
Trauma Injury; Brain Injuries; Abdominal Sepsis; Pancreatitis; Meningitis; Encephalitis; Seizures; Acute Respiratory Distress Syndrome
- Country
- Russia
- Type
- Trial
- Brief status
- Completed
- Reviewed
University Clinical Hospital named after V.V.Vinogradov (branch) of the Peoples' Friendship University of Russia named after Patrice Lumumba — Moscow
Recorded study locations: Endocarditis, Bacterial. Not an offer of treatment.
- Country
- Russia
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Singapore General Hospital
Personalized IV phages plus antibiotics for difficult implant-associated P. aeruginosa infection; local phage library and manufacture.
- Country
- Singapore
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
JAFRAL
Phage process development and manufacturing for human therapeutics, with fill/finish and other biologic services.
- Country
- Slovenia
- Type
- Supplier
- Brief status
- Research/development
- Reviewed
TASK / Phages4TB consortium
Mycobacteriophage discovery, ex-vivo sputum work and clinical trial preparation for pulmonary tuberculosis; planned adjunctive antibiotics.
- Country
- South Africa
- Type
- Company
- Brief status
- Research/development
- Reviewed
MicrobiotiX Co Ltd
MP101 bacteriophage treatment for P. aeruginosa pneumonia. Official August 2026 release reports completion of the sentinel cohort in first-in-human phase1 trial.
- Country
- South Korea
- Type
- Company
- Brief status
- Research/development
- Reviewed
MP101-1001 (NCT07492771)
Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection
- Country
- South Korea
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Severance Hospital — MP101 pneumonia trial
Phase1 adults with acute P. aeruginosa pneumonia; isolate must be susceptible to MP101 and not susceptible to current antibiotic therapy per protocol.
- Country
- South Korea
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Severance Hospital — Seoul, Seodaemun-gu
Recorded study locations: Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- South Korea
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Evolving Therapeutics
Phage production collaboration with the I2SysBio laboratory; this is a supplier record, not a treatment clinic.
- Country
- Spain
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
Hospital Clinico Universitario Virgen de la Arrixaca — El Palmar, Murcia
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Spain
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
I2SysBio / University of Valencia-CSIC phage group
Institutional reports describe phage preparation for compassionate treatments, including respiratory infections in people with cystic fibrosis.
- Country
- Spain
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
INIBIC / CHUAC MicroTM phage research group
Institutional research group studying phage therapy, phage-host interactions and approaches to antibiotic-resistant infections.
- Country
- Spain
- Type
- Research
- Brief status
- Research/development
- Reviewed
La Fe University Hospital phage therapy activity
Reported nebulized phage treatment in a cystic fibrosis respiratory-infection case, in collaboration with I2SysBio and Yale.
- Country
- Spain
- Type
- Center
- Brief status
- Case-by-case; Intake unconfirmed
- Reviewed
Vall d'Hebron Barcelona Hospital Campus — Barcelona
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- Spain
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Virgen del Rocío Hospital phage therapy activity
Reported nebulized phage treatment in a cystic fibrosis respiratory-infection case, in collaboration with I2SysBio and Yale.
- Country
- Spain
- Type
- Center
- Brief status
- Case-by-case; Intake unconfirmed
- Reviewed
GLORIA (NCT06605651)
Hip Prosthesis Infection; Knee Prosthesis Infection
- Country
- Spain; France; Netherlands
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Karolinska University Hospital / Karolinska Institutet phage program
CF respiratory infection trial plans; clinical microbiology, Stockholm CF Center, infectious diseases and trauma/orthopedics collaboration.
- Country
- Sweden
- Type
- Research
- Brief status
- Intake unconfirmed
- Reviewed
Balgrist Phage Therapy and Research / REPhRAME
Recurrent urinary tract infections; REPhRAME plans engineered E. coli phages followed by microbiota transfer.
- Country
- Switzerland
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Centre Hospitalier Universitaire Vaudois — Lausanne
Recorded study locations: Wound Infection. Not an offer of treatment.
- Country
- Switzerland
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
CHUV bacteriophage and phagotherapy laboratory
Phage and lysin research, experimental development and rare exceptional clinical use context.
- Country
- Switzerland
- Type
- Research
- Brief status
- Research/development
- Reviewed
Geneva University Hospitals (HUG) clinical phage experience
Documented difficult respiratory infection treatment, with additional pharmacy case experience.
- Country
- Switzerland
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Micreos Pharmaceuticals AG / Micreos Group
Engineered endolysins, including MEndoB for S. aureus-associated atopic dermatitis; phage-derived enzymes rather than live therapeutic phage preparations.
- Country
- Switzerland; Netherlands
- Type
- Company
- Brief status
- Research/development
- Reviewed
Mahidol University / Siriraj phage research
Phage diagnostics and therapeutic discovery for AMR organisms, including biofilm/resistance laboratory studies.
- Country
- Thailand
- Type
- Research
- Brief status
- Research/development
- Reviewed
PrimaVac / PRIMAFAG
Current site describes phage-containing dietary supplements for microbial balance and hygiene products, rather than an established clinical infection-treatment service.
- Country
- Ukraine
- Type
- Supplier
- Brief status
- Provider-listed inquiry route
- Reviewed
Biocontrol Ltd
Historical phage-development company.
- Country
- United Kingdom
- Type
- Company
- Brief status
- Acquired by AmpliPhi in 2011
- Reviewed
Great Ormond Street Hospital (GOSH)
Laboratory support for resistant infections; historical pediatric CF/transplant-associated Mycobacterium abscessus treatment.
- Country
- United Kingdom
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
NexaBiome (formerly Fixed Phage)
Phage library, formulation/immobilization and human therapeutic development alongside other applications.
- Country
- United Kingdom
- Type
- Company
- Brief status
- Research/development
- Reviewed
NHS Tayside / Ninewells phage therapy program
Unlicensed physician-led use for difficult infections, including when antibiotics or surgery fail or cannot be used.
- Country
- United Kingdom
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
PDFI (NCT04289948)
Diabetes; Diabetic Foot; Diabetic Foot Infection
- Country
- United Kingdom
- Type
- Trial
- Brief status
- Withdrawn
- Reviewed
Phage UK
Nonprofit advocacy, clinician network and access support; no directly treating service established.
- Country
- United Kingdom
- Type
- Facilitator
- Brief status
- Status unconfirmed
- Reviewed
SASPiPhi Limited / STEPS-CF
Phase 1b/2a IV engineered SASPject PT3.9 for adults aged 18–60 with CF-associated susceptible P. aeruginosa infection; projected first enrollment January 1, 2027.
- Country
- United Kingdom
- Type
- Company
- Brief status
- Research/development
- Reviewed
- Country
- United Kingdom
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
UK Phage Therapy
Clinical support and manufacturing/access coordination; not itself confirmed as a treating clinic.
- Country
- United Kingdom
- Type
- Facilitator
- Brief status
- Status unconfirmed
- Reviewed
University Hospitals Derby and Burton NHS Foundation Trust — Derby, Derbyshire
Recorded study locations: Diabetes; Diabetic Foot; Diabetic Foot Infection. Not an offer of treatment.
- Country
- United Kingdom
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Exeter phage research / phage library
Phage discovery, research supply and development, including collaborations relevant to difficult infections.
- Country
- United Kingdom
- Type
- Research
- Brief status
- Research/development
- Reviewed
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa (NCT05453578)
Bacterial Disease Carrier; Cystic Fibrosis
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects (NCT05277350)
E.Coli Infections; Bloodstream Infection
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults (NCT04737876)
Healthy Volunteers
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
ACTIVE2 (NCT05269134)
Prosthetic Joint Infection
- Country
- United States
- Type
- Trial
- Brief status
- Withdrawn
- Reviewed
AdMed Research — Miami, Florida
Recorded study locations: Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
AmpliPhi Biosciences
Historical phage-development company.
- Country
- United States
- Type
- Company
- Brief status
- Renamed Armata in 2019
- Reviewed
AMPM Research Clinic — Miami Gardens, Florida
Recorded study locations: Urinary Tract Infections; Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Armata Pharmaceuticals
AP-SA02 S. aureus complicated bacteremia; AP-PA02 CF/non-CF bronchiectasis. Prior trials completed. Legacy AB-PA01/AB-SA01 expanded access no longer available.
- Country
- United States
- Type
- Company
- Brief status
- Research/development
- Reviewed
Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (NCT02757755)
Healthy Volunteers
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
Avanza Medical Center — Pensacola, Florida
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Bacteriophage Therapy in Patients With Prosthetic Joint Infections (NCT04787250)
Prosthetic Joint Infection
- Country
- United States
- Type
- Trial
- Brief status
- Withdrawn
- Reviewed
Bacteriophage Therapy in Patients With Urinary Tract Infections (NCT04287478)
Urinary Tract Infection Bacterial
- Country
- United States
- Type
- Trial
- Brief status
- Terminated
- Reviewed
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection (NCT07275905)
Cystic Fibrosis (CF); Achromobacter Infection
- Country
- United States
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Banner University Medical Center — Tucson, Arizona
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Baylor College of Medicine — Houston, Texas
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Baylor College of Medicine TAILOR
Phage discovery, characterization and personalized preparation supporting treating clinicians; also non-clinical applications.
- Country
- United States
- Type
- Supplier
- Brief status
- Case-by-case; Intake unconfirmed
- Reviewed
Baylor College of Medicine, Texas Children Clinic — Houston, Texas
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Bio X Cell Research LLC — San Antonio, Texas
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Biomarkers of Phage Treatment Response in NTM and Other Infections (NCT07076238)
Nontuberculous Mycobacterial Lung Disease
- Country
- United States
- Type
- Observational study
- Brief status
- Recruiting
- Reviewed
Boston Children's Hospital — Boston, Massachusetts
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Chronic Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Boston Childrens Hospital — Boston, Massachusetts
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
Brigham & Women's Hospital — Boston, Massachusetts
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
C3J Therapeutics
Historical Armata predecessor company.
- Country
- United States
- Type
- Company
- Brief status
- Merged into Armata 2019
- Reviewed
Case Western Reserve University — Cleveland, Ohio
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Central Florida Pulmonary Group — Orlando, Florida
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Children's Hospital Los Angeles — Los Angeles, California
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Children's Hospital of Los Angeles — Los Angeles, California
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
Children's National Medical Center — Washington D.C., District of Columbia
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Childrens Hospital Colorado — Denver, Colorado
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
Cincinnati Children's Hospital — Cincinnati, Ohio
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
City of Hope — Duarte, California
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Clemente Clinical Research — Los Angeles, California
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Clinical Trials Center, WRAIR — Silver Spring, Maryland
Recorded study locations: Healthy Volunteers. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Colorado State University — Fort Collins, Colorado
Recorded study locations: Mild Gastrointestinal Symptoms in Healthy Adults; Gastrointestinal Symptoms; Skin Quality. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Columbia University — New York, New York
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
CurAlta Foot and Ankle — Westwood, New Jersey
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
DANCE (NCT05177107)
Osteomyelitis; Diabetic Foot Osteomyelitis
- Country
- United States
- Type
- Trial
- Brief status
- Terminated
- Reviewed
Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
DHR Health Institute for Research and Development — Edinburg, Texas
Recorded study locations: Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
doTERRA International — Pleasant Grove, Utah
Recorded study locations: Healthy. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Duke University Medical Center — Durham, North Carolina
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
ELIMINATE (NCT05488340)
Urinary Tract Infections
- Country
- United States
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Emory University - Adult Cystic Fibrosis Program — Atlanta, Georgia
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Emory University Hospital Midtown — Atlanta, Georgia
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Food and Nutrition Clinical Research Lab(FNCRL), Colorado State University — Fort Collins, Colorado
Recorded study locations: Gastrointestinal Dysfunction. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Foot & Ankle Center of Illinois — Springfield, Illinois
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Foot and Ankle Specialists of the Mid-Atlantic — Salem, Virginia
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Fred Hutchinson Cancer Center — Seattle, Washington
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Futuro Clinical Trials, LLC — McAllen, Texas
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine — Washington D.C., District of Columbia
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Gladstone Center for PhAIge Therapy
2026 research center using phage engineering, computational tools, susceptibility prediction and preclinical infection models.
- Country
- United States
- Type
- Research
- Brief status
- Research/development
- Reviewed
Harbor Hospital / UCLA — Torrance, California
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Harper University Hospital — Detroit, Michigan
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Hartford Health Care Bone & Joint Insitute — Hartford, Connecticut
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Henry Ford Health — Detroit, Michigan
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Henry Ford Health System — Detroit, Michigan
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Henry Ford Hospital — Detroit, Michigan
Recorded study locations: Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Holy Cross Health — Fort Lauderdale, Florida
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Holy Name Medical Center — Teaneck, New Jersey
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Icahn School of Medicine at Mount Sinai — New York, New York
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Icahn School of Medicine at Mount Sinai Hospital — New York, New York
Recorded study locations: Crohn Disease. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Infectious Disease Consultants od the Treasure Coast — Sebastian, Florida
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Innovation Medical Research Center — Palmetto Bay, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Innovation Medical Research Center, Inc — Palmetto Bay, Florida
Recorded study locations: Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Intralytix
Supplier expanded access plus EcoActive, ShigActive and VRELysin clinical development; fixed indications and product availability limit access.
- Country
- United States
- Type
- Supplier
- Brief status
- Official referral/inquiry route
- Reviewed
James J. Peters VA Medical Center — The Bronx, New York
Recorded study locations: Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Joe DiMaggio Children's Health — Hollywood, Florida
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Joe DiMaggio Children's Hospital — Hollywood, Florida
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
John Hopkins University — Baltimore, Maryland
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary; E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Mixed trial statuses
- Reviewed
Johns Hopkins — EcoActive Crohn's research site
EcoActive oral E. coli phage preparation for adults with inactive Crohn's and intestinal adherent-invasive E. coli.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Johns Hopkins Green Spring Station — Lutherville, Maryland
Recorded study locations: Crohn Disease. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Johns Hopkins University — Baltimore, Maryland
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus; Bacterial Disease Carrier. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Johns Hopkins University School of Medicine — Baltimore, Maryland
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Locus Biosciences
LBP-EC01 engineered CRISPR-Cas3 E. coli phage therapy for drug-resistant acute uncomplicated UTI; other pipeline programs are separate development work.
- Country
- United States
- Type
- Company
- Brief status
- Official referral/inquiry route
- Reviewed
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Torrance, California
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Massachusetts General Hospital — Boston, Massachusetts
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Mayo Clinic — Rochester, Minnesota
Recorded study locations: Prosthetic Joint Infection; Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Mayo Clinic Phage Program Biobank (NCT05314426)
Bacteriophage Therapy
- Country
- United States
- Type
- Observational study
- Brief status
- Invitation only
- Reviewed
Mayo Clinic Phage Therapy Program
Clinical program with musculoskeletal and device-associated infection experience; published LVAD case. Observational phage biobank is enrolling by invitation.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Mayo Clinic Rochester — Rochester, Minnesota
Recorded study locations: Bacteriophage Therapy. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
Mayo Clinic/Pulmonary, Critical Care, and Sleep Medicine — Jacksonville, Florida
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Medical Facility — Cincinnati, Ohio
Recorded study locations: Healthy Volunteers. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Medical University of South Carolina — Charleston, South Carolina
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Chronic Pseudomonas Aeruginosa Infection; Non-cystic Fibrosis Bronchiectasis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Medpace Clinical Pharmacology — Cincinnati, Ohio
Recorded study locations: E.Coli Infections; Bloodstream Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Methodist Hospital Research Institute - Houston — Houston, Texas
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Michael E. DeBakey VA Medical Center — Houston, Texas
Recorded study locations: Bacteriuria; Spinal Cord Injuries; Asymptomatic Bacteriuria; Escherichia Coli. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Michael E. DeBakey VA Medical Center — SCI bacteriuria trial
Spinal cord injury E. coli bacteriuria; personalized intravesical phage/placebo research.
- Country
- United States
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Michigan Medicine — Ann Arbor, Michigan
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Montefiore Medical Center — The Bronx, New York
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Mount Sinai — EcoActive Crohn's research site
EcoActive in inactive Crohn's with intestinal adherent-invasive E. coli.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
National Jewish Health — Denver, Colorado
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary; Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Mixed trial statuses
- Reviewed
National Jewish Health / POSTSTAMP
Invitation-only observational cohort for persistent NTM infection after at least 12 months of guideline-based therapy in people with cystic fibrosis; usual antibiotics continue. Earlier institutional evidence describes a 2022 Mycobacterium abscessus case.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Nationwide Children's Hospital — Columbus, Ohio
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Chronic Pseudomonas Aeruginosa Infection; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
- Country
- United States
- Type
- Adjacent product trial
- Brief status
- Completed
- Reviewed
New England Baptist Hospital — Boston, Massachusetts
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
New York Medical College — Hawthorne, New York
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection; Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
New York Medical College — Valhalla, New York
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Chronic Pseudomonas Aeruginosa Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
NorthBay Healthcare — Fairfield, California
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Northwell Health — New Hyde Park, New York
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Northwell Health — New York, New York
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Northwestern University — Chicago, Illinois
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
NYU Langone Health — New York, New York
Recorded study locations: Nontuberculous Mycobacterial Lung Disease. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
NYU Langone NTM/bronchiectasis phage program
Selected severe NTM infection with bronchiectasis treated under individualized IND; collaboration with Pittsburgh for matching. Biomarker study also covers other infections.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
Oregon Health & Science University — Portland, Oregon
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Phage (NCT06559618)
Bacteriuria; Spinal Cord Injuries; Asymptomatic Bacteriuria; Escherichia Coli
- Country
- United States
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Phage 3Determination of Phage/Probiotic Synergistic Effects on Gastrointestinal Health (NCT05750433)
Gastrointestinal Dysfunction
- Country
- United States
- Type
- Adjacent product trial
- Brief status
- Completed
- Reviewed
Phage International Inc.
Former US parent of Phage Therapy Center LTD, Georgia.
- Country
- United States
- Type
- Company
- Brief status
- Ceased operations 2023
- Reviewed
Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients (NCT06409819)
Urinary Tract Infection, Recurrent
- Country
- United States
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Phage-CLEAR (NCT07816809)
Gastrointestinal Symptoms; Skin Quality
- Country
- United States
- Type
- Adjacent product trial
- Brief status
- Recruiting
- Reviewed
PHAGE2 (NCT04511221)
Mild Gastrointestinal Symptoms in Healthy Adults
- Country
- United States
- Type
- Adjacent product trial
- Brief status
- Completed
- Reviewed
PhagePro
Company explicitly describes itself as preclinical; ProphaLytic-Vc cholera-prevention development.
- Country
- United States
- Type
- Company
- Brief status
- Research/development
- Reviewed
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant (NCT06938867)
E Coli Infections; Allogenic Transplant Patients
- Country
- United States
- Type
- Trial
- Brief status
- Recruiting
- Reviewed
Phiogen
Developing evolved phages for drug-resistant pathogens; company reports historical emergency clinical use.
- Country
- United States
- Type
- Company
- Brief status
- Research/development
- Reviewed
PhoenixAH (NCT06750588)
Alcohol-Associated Hepatitis
- Country
- United States
- Type
- Trial
- Brief status
- Not yet recruiting
- Reviewed
Pinnacle Research Group — Anniston, Alabama
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Pittsburgh Phage Program (P3), University of Pittsburgh/UPMC
Multidisciplinary compassionate use, phage discovery/manufacturing and clinical trials; AchromoPhage adults with CF and chronic Achromobacter infection is recruiting at Pittsburgh.
- Country
- United States
- Type
- Center
- Brief status
- Case-by-case; Official referral/inquiry route
- Reviewed
Podiatry 1st / Gateway Clinical Trials — O'Fallon, Illinois
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
POSTSTAMP (NCT06262282)
Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary
- Country
- United States
- Type
- Observational study
- Brief status
- Invitation only
- Reviewed
Providence Alaska Medical Center — Anchorage, Alaska
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Ralph H. Johnson VA Medical Center — Charleston, South Carolina
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Regional One Healthcare — Memphis, Tennessee
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Research Site 102 — Doral, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 103 — Miami, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 118 — Winston-Salem, North Carolina
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Completed (trial)
- Reviewed
Research Site 120 — Boston, Massachusetts
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Completed (trial)
- Reviewed
Research Site 123 — Los Angeles, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 125 — Montebello, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Completed (trial)
- Reviewed
Research Site 126 — Tustin, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 131 — Lancaster, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 137 — San Diego, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 138 — Fresno, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Completed (trial)
- Reviewed
Research Site 140 — Jensen Beach, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Completed (trial)
- Reviewed
Research Site 145 — Raleigh, North Carolina
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 149 — Miami, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 151 — Hialeah, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 152 — Murrieta, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 153 — Ocala, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Research Site 154 — St Louis, Missouri
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Rhode Island Hospital — Providence, Rhode Island
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Rocky Mountain Regional VA Medical Center — Aurora, Colorado
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Rocky Mountain VA — Aurora, Colorado
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Rutgers Robert Wood Johnson Medical School — New Brunswick, New Jersey
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Non-cystic Fibrosis Bronchiectasis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Rutgers, Robert Wood Johnson Medical School — New Brunswick, New Jersey
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
- Country
- United States
- Type
- Trial
- Brief status
- Conflicting status
- Reviewed
Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects (NCT05715619)
Vancomycin-Resistant Enterococcal Colonization
- Country
- United States
- Type
- Trial
- Brief status
- Suspended
- Reviewed
- Country
- United States
- Type
- Trial
- Brief status
- Active, not recruiting
- Reviewed
Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli (NCT04191148)
Urinary Tract Infections
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
Salem VA — Salem, Virginia
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Seattle Children's Hospital — Seattle, Washington
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Sinai Hospital of Baltimore — Baltimore, Maryland
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Snake River Research — Idaho Falls, Idaho
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Southern Arizona VA Health Care System — Tuscon, Arizona
Recorded study locations: Osteomyelitis; Diabetic Foot Osteomyelitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower — Los Angeles, California
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Southern California Research Center, inc — Coronado, California
Recorded study locations: Alcohol-Associated Hepatitis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
Southweast Regional Wound Care Center — Lubbock, Texas
Recorded study locations: Venous Leg Ulcers. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Southwest General Healthcare Center — Fort Myers, Florida
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Southwestern Medical Center at Dallas — Dallas, Texas
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
St. Luke's Cystic Fibrosis Center of Idaho — Boise, Idaho
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
St. Lukes Hospital — Boise, Idaho
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Stanford Center for Phage Pharmaceuticals
2026 NIAID-supported translational program led by Paul Bollyky; initial focus on developing lung-delivery phages for Pseudomonas infection in CF.
- Country
- United States
- Type
- Research
- Brief status
- Research/development
- Reviewed
Stanford University — Palo Alto, California
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Stanford University — Stanford, California
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
SWARM-Pa (NCT04596319)
Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
Tabula Bioscience
Investigational individualized phage therapies; serious bacterial infections without satisfactory alternatives and infeasible trial participation; isolate matching, manufacturing capacity and regulatory/ethical requirements determine supply.
- Country
- United States
- Type
- Company
- Brief status
- Official referral/inquiry route
- Reviewed
Tailwind (NCT05616221)
Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
TecTum Medical Research, Inc. — Hollywood, Florida
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Texas A&M Center for Phage Technology
Clinical-support phage sourcing plus bacterial/phage engineering and other preclinical projects.
- Country
- United States
- Type
- Supplier
- Brief status
- Intake unconfirmed
- Reviewed
The Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The Jamaica Hospital Medical Center — Jamaica, New York
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The University of Alabama at Birmingham — Birmingham, Alabama
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson — Tucson, Arizona
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The University of Kansas Medical Center — Kansas City, Kansas
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
The University of Kansas Medical Center / Dept of Medicine — Kansas City, Kansas
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Tilda Research — Irvine, California
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Tolka AI Therapeutics
Personalized phages for NTM lung disease, initially Mycobacterium abscessus complex; serious/life-threatening disease without viable options, trial ineligibility, favorable assessment, supply and local regulatory/ethical permission.
- Country
- United States
- Type
- Company
- Brief status
- Provider-listed inquiry route
- Reviewed
Tranquil Clinical Research — Webster, Texas
Recorded study locations: Diabetic Foot Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Tufts Medical Center — Boston, Massachusetts
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
UC San Diego IPATH
Compassionate-use support for serious resistant or device-associated bacterial infections; prioritizes life/limb-threatening cases, complicated UTIs, transplant and implant-associated infections. Matching, clinical review, supply and regulatory authorization remain necessary.
- Country
- United States
- Type
- Center
- Brief status
- Case-by-case; Official referral/inquiry route
- Reviewed
UCONN Health — Farmington, Connecticut
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
UCSF — former BX004 phage trial site
Former phase 2b inhaled BX004 research for adults with CF and chronic Pseudomonas lung infection.
- Country
- United States
- Type
- Center
- Brief status
- Historical/inactive
- Reviewed
Universal Axon - Homestead, LL — Homestead, Florida
Recorded study locations: Urinary Tract Infections. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Universal Axon Clinical Research — Doral, Florida
Recorded study locations: Urinary Tract Infections; Urinary Tract Infection Bacterial. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University Hospitals Cleveland Medical Center — Cleveland, Ohio
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University Hospitals of Cleveland Medical Center — Cleveland, Ohio
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University Hospitals Rainbow Babies and Children's Hospital — Cleveland, Ohio
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Alabama — Birmingham, Alabama
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Alabama at Birmingham — Birmingham, Alabama
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
University of Arkansas for Medical Sciences — Little Rock, Arkansas
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
University of California — San Diego, California
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of California Davis Health — Sacramento, California
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California Los Angeles Medical Center - Westwood Clinic — Los Angeles, California
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California San Diego (UCSD) — San Diego, California
Recorded study locations: Cystic Fibrosis (CF); Achromobacter Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Not yet recruiting (trial)
- Reviewed
University of California San Diego Medical Center — San Diego, California
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California San Francisco — San Francisco, California
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
University of California, Los Angeles (UCLA) - Medical Center — Los Angeles, California
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California, San Diego — La Jolla, California
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis; Urinary Tract Infection, Recurrent. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
University of California, San Diego (UCSD) - Antiviral Research Center (AVRC) — La Jolla, California
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California, San Diego (UCSD) - Medical Center — La Jolla, California
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of California, San Francisco — San Francisco, California
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
University of Cincinnati - College of Medicine — Cincinnati, Ohio
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Florida - Jacksonville — Jacksonville, Florida
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Florida — Gainesville, Florida
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Florida (UF) - Division of Infectious Disease — Gainesville, Florida
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Iowa — Iowa City, Iowa
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Maryland Medical Center — Baltimore, Maryland
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Maryland School of Medicine — James Doub clinical research
Clinical/translational musculoskeletal infection program and phage research; profile reports treatment protocols and research funding.
- Country
- United States
- Type
- Center
- Brief status
- Intake unconfirmed
- Reviewed
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health — Baltimore, Maryland
Recorded study locations: Shigellosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Active, not recruiting (trial)
- Reviewed
University of Miami — Miami, Florida
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Michigan — Ann Arbor, Michigan
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus; Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Minnesota — Minneapolis, Minnesota
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
University of Minnesota Medical Center — Minneapolis, Minnesota
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of North Carolina - Chapel Hill School of Medicine — Chapel Hill, North Carolina
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Pennslyvania — Philadelphia, Pennsylvania
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Pittsburgh — Pittsburgh, Pennsylvania
Recorded study locations: Cystic Fibrosis (CF); Achromobacter Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of South Florida — Tampa, Florida
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of South Florida/Tampa General Hospital — Tampa, Florida
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Southern California Keck School of Medicine — Los Angeles, California
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Texas Health Science Center at Tyler — Tyler, Texas
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Texas MD Anderson Cancer Center — Houston, Texas
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
University of Texas Southwestern — Dallas, Texas
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Texas Southwestern Medical Center — Dallas, Texas
Recorded study locations: Urinary Tract Infection Bacterial; Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Utah — Salt Lake City, Utah
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
University of Vermont — Burlington, Vermont
Recorded study locations: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Virginia — Charlottesville, Virginia
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Washington — Seattle, Washington
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Invitation only (trial)
- Reviewed
University of Washington Medical Center — Seattle, Washington
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
University of Wisconsin — Madison, Wisconsin
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
UPMC — Pittsburgh, Pennsylvania
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
UPMC Presbyterian — Pittsburgh, Pennsylvania
Recorded study locations: Vancomycin-Resistant Enterococcal Colonization. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Suspended (trial)
- Reviewed
UT Health San Antonio phage research collaboration
Exploratory phage persistence and production research with UTSA, Texas Biomedical and Brooke Army Medical Center; Phage Refinery commercialization link.
- Country
- United States
- Type
- Research
- Brief status
- Research/development
- Reviewed
Vanderbilt University Medical Center — Nashville, Tennessee
Recorded study locations: Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal; Bacterial Disease Carrier; Non-cystic Fibrosis Bronchiectasis; Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF). Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Conflicting status (trial)
- Reviewed
Velocity Clinical Research — Mobile, Alabama
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Virginia Commonwealth University (VCU) — Richmond, Virginia
Recorded study locations: Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Wake Forest University Health Sciences — Winston-Salem, North Carolina
Recorded study locations: Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Washington University in St Louis — St Louis, Missouri
Recorded study locations: Bacteriuria; Spinal Cord Injuries; Asymptomatic Bacteriuria; Escherichia Coli. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
Washington University School of Medicine — SCI bacteriuria trial
Randomized intravesical matched phage/placebo trial in adults with spinal cord injury and E. coli bacteriuria.
- Country
- United States
- Type
- Center
- Brief status
- Official referral/inquiry route
- Reviewed
Weill Cornell Medicine — New York, New York
Recorded study locations: E Coli Infections; Allogenic Transplant Patients. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Recruiting (trial)
- Reviewed
William Beaumont Hospital — Royal Oak, Michigan
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
WPP-201 (NCT00663091)
Venous Leg Ulcers
- Country
- United States
- Type
- Trial
- Brief status
- Completed
- Reviewed
WVU Medicine JW Ruby Memorial Hospital — Morgantown, West Virginia
Recorded study locations: Prosthetic Joint Infection. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Yale New Haven Hospital — New Haven, Connecticut
Recorded study locations: Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Yale North Haven Medical Center- Winchester Center for Lung Disease — North Haven, Connecticut
Recorded study locations: Bacterial Disease Carrier; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Yale Phage Therapy Program
Clinical phage therapy at Yale and collaborating clinics for antibiotic-resistant bacterial infection; individualized compassionate-use eligibility.
- Country
- United States
- Type
- Center
- Brief status
- Case-by-case; Official referral/inquiry route
- Reviewed
Yale University — New Haven, Connecticut
Recorded study locations: Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis. Not an offer of treatment.
- Country
- United States
- Type
- Trial site
- Brief status
- Historical trial site
- Reviewed
Kinzbio personalized phage supply
Individualized treatment/prevention of multidrug-resistant bacterial infection; clinician/institution-mediated supply rather than a verified independent destination clinic.
- Country
- Uruguay
- Type
- Supplier
- Brief status
- Official referral/inquiry route
- Reviewed
Bacteriophage Therapy in Tonsillitis (NCT04682964)
Acute Tonsillitis
- Country
- Uzbekistan
- Type
- Trial
- Brief status
- Active, not recruiting
- Reviewed
Tashkent Pediatric Medical Institute — Tashkent
Recorded study locations: Acute Tonsillitis. Not an offer of treatment.
- Country
- Uzbekistan
- Type
- Trial site
- Brief status
- Active, not recruiting (trial)
- Reviewed
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.